Trading Report: Today, Quantbot Technologies LP Invests $139,000 in Amphastar Pharmaceuticals Inc. (AMPH)

Today, Quantbot Technologies LP Invests $139,000 in Amphastar Pharmaceuticals Inc. (AMPH)

Quantbot Technologies LP acquired a new stake in Amphastar Pharmaceuticals Inc. (NASDAQ:AMPH) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 7,360 shares of the company’s stock, valued at approximately $139,000.

Other large investors have also added to or reduced their stakes in the company. Acrospire Investment Management LLC raised its stake in Amphastar Pharmaceuticals by 57.5% in the second quarter. Acrospire Investment Management LLC now owns 6,791 shares of the company’s stock valued at $109,000 after buying an additional 2,479 shares in the last quarter. Atria Investments LLC acquired a new stake in Amphastar Pharmaceuticals during the third quarter valued at approximately $190,000. C M Bidwell & Associates Ltd. acquired a new stake in Amphastar Pharmaceuticals during the second quarter valued at approximately $207,000. Simplex Trading LLC acquired a new stake in Amphastar Pharmaceuticals during the third quarter valued at approximately $277,000. Finally, Bank of Montreal Can acquired a new stake in Amphastar Pharmaceuticals during the second quarter valued at approximately $292,000. Institutional investors and hedge funds own 44.86% of the company’s stock.

Shares of Amphastar Pharmaceuticals Inc. (NASDAQ:AMPH) traded down 0.05% on Friday, reaching $20.64. 94,139 shares of the company traded hands. Amphastar Pharmaceuticals Inc. has a 52-week low of $10.50 and a 52-week high of $21.66. The firm has a 50-day moving average of $19.12 and a 200-day moving average of $17.66. The company has a market capitalization of $949.91 million, a PE ratio of 45.07 and a beta of 1.86.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its quarterly earnings results on Tuesday, November 8th. The company reported $0.14 EPS for the quarter, beating analysts’ consensus estimates of $0.03 by $0.11. The company had revenue of $64.20 million for the quarter, compared to analyst estimates of $65.12 million. Amphastar Pharmaceuticals had a return on equity of 6.79% and a net margin of 7.75%. The company’s quarterly revenue was up .5% compared to the same quarter last year. During the same period last year, the company earned ($0.01) earnings per share. On average, equities research analysts forecast that Amphastar Pharmaceuticals Inc. will post $0.47 earnings per share for the current fiscal year.

AMPH has been the topic of several recent research reports. Zacks Investment Research upgraded shares of Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating and set a $21.00 price objective on the stock in a research report on Tuesday, October 11th. Needham & Company LLC boosted their price objective on shares of Amphastar Pharmaceuticals from $20.00 to $22.00 and gave the stock a “buy” rating in a research report on Tuesday, August 9th. Jefferies Group boosted their price objective on shares of Amphastar Pharmaceuticals from $16.00 to $19.00 and gave the stock a “buy” rating in a research report on Tuesday, August 9th. BMO Capital Markets reissued a “hold” rating and issued a $17.00 target price on shares of Amphastar Pharmaceuticals in a research note on Tuesday, August 9th. Finally, Piper Jaffray Cos. reissued an “overweight” rating and issued a $23.00 target price (up previously from $22.00) on shares of Amphastar Pharmaceuticals in a research note on Wednesday, September 7th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Amphastar Pharmaceuticals has an average rating of “Buy” and a consensus target price of $20.17.

In other news, insider Jason B. Shandell sold 56,996 shares of the firm’s stock in a transaction on Monday, September 26th. The stock was sold at an average price of $19.50, for a total transaction of $1,111,422.00. Following the transaction, the insider now directly owns 259,957 shares of the company’s stock, valued at $5,069,161.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Howard Lee sold 10,381 shares of the firm’s stock in a transaction on Thursday, September 1st. The shares were sold at an average price of $18.78, for a total value of $194,955.18. Following the transaction, the director now directly owns 125 shares in the company, valued at $2,347.50. The disclosure for this sale can be found here. Insiders own 29.30% of the company’s stock.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable and inhalation products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.

Related posts

Leave a Comment